Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a leading clinical-stage pharmaceutical company that primarily focuses on the development and commercialization of unique drugs designed to specifically treat inflammatory diseases, fibrotic diseases, and cancer. The company is at the forefront of pioneering innovative therapies that improve the lives of those living with severe, chronic, and life-threatening diseases.
Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals Holdings, Inc. operates through its single segment, which is Research and Development. Its commitment to provide cutting-edge solutions to global health challenges has placed it among the leading organizations in the pharmaceutical industry.
CRBP's flagship product candidate is Lenabasum, a synthetic, oral, small-molecule cannabinoid receptor type 2 (CB2) agonist that the company is studying with the aim to resolve chronic inflammation and halt fibrotic processes without causing weak immune responses. Clinical trials of Lenabasum are currently underway for treating diseases such as systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Apart from Lenabasum, Corbus also has a significant pipeline of other preclinical drug candidates, such as CRB-4001, a second-generation, peripherally-restricted, CB1 inverse agonist. This drug is specifically targeted at metabolic disorders, including nonalcoholic steatohepatitis (NASH) and type-1 diabetes.
Corbus places a high premium on collaborations and partnerships to advance its proprietary drug development. It has forged alliances with institutions such as the Cystic Fibrosis Foundation and the University of Massachusetts Medical School. These strategic collaborations are aimed to promote the development of novel drug candidates, leverage external expertise, and facilitate clinical studies.
While Corbus faces considerable competition in the pharmaceutical industry, its relentless pursuit for breakthrough drugs and commitment to contributing to better healthcare distinguished it in thefield of innovative therapeutic targets. The company continues to focus on advancing its research and clinical programs, with the goal of delivering safe, effective, and approved drugs that can meaningfully improve the overall quality of life for patients suffering from debilitating diseases.
Despite the inherent risks and uncertainties associated with drug development, Corbus Pharmaceuticals Holdings, Inc. has demonstrated resilience and adaptability, underlining its dedication to its mission. Its ground-breaking work continues to unlock potential therapeutic benefits, ensuring that Corbus remains a significant player in the pharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is gaining attention within the cannabis stocks sector following its recent report of positive topline data from the Canyon study for its oral CB-one receptor inverse agonist in obesity. This development highlights the company's potential to extend cannabinoid-pathway drug development. The article emphasizes that sustained market interest will depend on CRBP's consistent operational execution, customer response, and financial results in the upcoming reporting cycles, rather than just the initial announcement.
Corbus Pharmaceuticals Holdings Inc. experienced a significant drop, with its stock sliding by 14.4%. This performance indicates that the company is currently underperforming compared to its peers in the market. Investors may want to monitor Corbus Pharmaceuticals' future movements and market conditions.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has published a slide deck detailing the Phase 1b topline results for its drug candidate CRB-913, which is being investigated for obesity and its potential as a weight loss therapy. The information is presented in a slideshow format, likely containing key data and findings from the study. This release is intended for investors and stakeholders, providing an update on the drug's development.
_07_03_2026_03_50_21_133108.jpg)
Corbus Pharmaceuticals insider Ben Yong sold 2,000 shares of the company's stock at $7.84 per share on September 14, 2026. This transaction reduced his holdings by approximately 17.6%, leaving him with 9,383 shares. The sale was disclosed via a Form 4 filing with the SEC, indicating an open-market or private sale.
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b trial for CRB-913, an oral non-incretin obesity treatment. The drug showed significant weight loss across all doses with a favorable safety profile, including fewer gastrointestinal adverse events and minimal psychiatric side effects compared to previous drugs and existing GLP-1 therapies. The company plans to engage with the FDA for a Phase 2 trial and explore combination therapies.
Corbus Pharmaceuticals (CRBP) stock is gaining attention due to an upcoming webcast presenting topline Phase 1b CANYON-1 data for its obesity drug candidate, CRB-913. Despite recent profit-taking and a quarterly net loss, the company maintains strong liquidity, making the webcast a critical volatility event for traders. The appointment of a new CMO with inducement stock options further signals leadership's commitment to long-term value in oncology and obesity pipelines.